Prognostic significance of T cell subsets in peripheral blood of B cell non-Hodgkin's lymphoma patients

Medical Oncology

Volumn 29, Issue 4, 2012, Pages 2364-2371

  Dehghani, Mehdi ^a   Sharifpour, Shokouh ^a   Amirghofran, Zahra ^b   Zare, Hamid Reza ^b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

International prognostic index; Non Hodgkin's lymphoma; T cell subsets

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; LYMPHOCYTE COUNT; MALE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; CD4-CD8 RATIO; FEMALE; FLOW CYTOMETRY; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; PROGNOSIS; T-LYMPHOCYTE SUBSETS;

EID: 84867996419     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0176-1     Document Type: Article

References (31)

1. Lichtman MA, Beutler E, Kipps TJ, et al. Williams text book of hematology.7th ed. New York, NY: Mc Graw Hill; 2006.
2. Betts GJ, Clarke SL, Richards HE, et al. Regulating the immune response to tumors. Adv Drug Deliv Rev. 2006;58:948-61.
3. Grulich AE, Vajdic CM, Cozen W. Altered immunity as a risk factor for non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev. 2007;16:405-8.
4. Vasei M, Kumar PV, Malekhosseini SA, Amirghofran Z. Primary T-cell lymphoma of the breast with lymphoepithelial lesion. A case report. APMIS. 1997;105:445-8.
5. Nogai H, Dörken B, Lenz G. Pathogenesis of Non-Hodgkin's lymphoma. J Clin Oncol. 2011;29:1803-11.
6. Sznurkowski JJ, Zawrocki A, Emerich J, et al. Prognostic significance of CD4+ and CD8+ T cell infiltration within cancer cell nests in vulvar squamous cell carcinoma. Int J Gynecol Cancer. 2011;21:717-21.
7. Waldner M, Schimanski CC, Neurath MF. Colon cancer and the immune system: the role of tumor invading T cells. World J Gastroenterol. 2006;12:7233-8.
8. Ansell SM, Stenson M, Habermann TM, et al. CD4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome. J Clin Oncol. 2001;19:720-6.
9. Wansom D, Light E, Worden F, et al. Correlation of cellular immunity with human papillomavirus status and outcome in patients with advanced oropharyngeal cancer. Arch Otolaryngol Head Neck Surg. 2010;136:1267-73.
10. Hernberg MM, Hahka-Kemppinen MH, Pyrhonen SO. The prognostic role of CD4+ and CD8+ lymphocytes during chemoimmunotherapy in metastatic melanoma. Melanoma Res. 2004;14:493-500.
11. Gorczyca W, Weisberger J, Liu Z, et al. An approach to diagnosis of T-cell lymphoproliferative disorders by flow cytometry. Cytometry. 2002;50:177-90.
12. Medeiros LJ, Harmon DC, Linggood RM, et al. Immunohistologic features predict clinical behavior of orbital and conjunctival lymphoid infiltrates. Blood. 1989;74:2121-9.
13. Slymen DJ, Miller TP, Lippman SM, et al. Immunobiologic factors predictive of clinical outcome in diffuse large-cell lymphoma. J Clin Oncol. 1990;8:986-93.
14. Mougiakakos D, Choudhury A, Lladser A, et al. Regulatory Tcells in cancer. Adv Cancer Res. 2010;107:57-117.
15. Feng LL, Wang X. Targeting Foxp3+ regulatory T cells-related immunosuppression for cancer immunotherapy. Chin Med J (Engl). 2010;123:3334-42.
16. + regulatory T cells in B-cell non-Hodgkin's lymphoma. Cancer Res. 2006;66:10145-52.
17. Brusko TM, Wasserfall CH, Clare-Salzler MJ, et al. Functional defects and the influence of age on the frequency of CD4+CD25+ T-cells in type 1 diabetes. Diabetes. 2005;54:1407-14.
18. Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:2373-80.
19. Kapplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-81.
20. Shahghasempour SH, Gerami M, Entezami Z. Enumeration of peripheral blood lymphocyte subsets in a healthy Iranian population. Arch Iran Med. 2001;4:80-3.
21. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood. 2006;108:804-8.
22. Chatzitolios A, Venizelos I, Tripsiannis G, et al. Prognostic significance of CD95, P53, and BCL2 expression in extranodal non-Hodgkin's lymphoma. Ann Hematol. 2010;89:889-96.
23. Váróczy L, Gergely L, Miltényi Z, et al. Can CD3+/HLA-DR+ activated T cells predict the prognosis of non-Hodgkin's lymphoma patients? Immunol Lett. 2005;97:155-7.
24. Xu Y, Kroft SH, McKenna RW, et al. Prognostic significance of tumour-infiltrating T lymphocytes and T-cell subsets in de novo diffuse large B-cell lymphoma: a multiparameter flow cytometry study. Br J Haematol. 2001;112:945-9.
25. Liu L, Yao J, Ding Q, et al. CD4+CD25 high regulatory cells in peripheral blood of NSCLC patients. J Huazhong Univ Sci Technol Med Sci. 2006;26:548-51.
26. Marshall NA, Culligan DJ, Tighe J, et al. The relationships between Epstein-Barr virus latent membrane protein 1 and regulatory T cells in Hodgkin's lymphoma. Exp Hematol. 2007;35:596-604.
27. Alvaro T, Lejeune M, Salvadó MT, et al. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol. 2006;24:5350-7.
28. Shi X, Zhang XS, Liu DG, et al. CD4+CD25+ T regulatory cells in peripheral blood of B-NHL patients with or without chemotherapy. Ai Zheng. 2004;23:597-601.
29. Tzankov A, Meier C, Hirschmann P, et al. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica. 2008;93:193-200.
30. Coupland SE. The challenge of the microenvironment in B-cell lymphomas. Histopathology. 2011;58:69-80.
31. Montserrat E, Campo E, Banham AH, et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood. 2006;108:2957-64.